NASDAQ:LVTX LAVA Therapeutics (LVTX) Stock Price, News & Analysis → Big Tech is spending billions each month on Nvidia’s AI superproject (From Weiss Ratings) (Ad) Free LVTX Stock Alerts $2.29 -0.04 (-1.72%) (As of 06/12/2024 ET) Add Compare Share Share Today's Range$2.22▼$2.3750-Day Range$2.21▼$3.3452-Week Range$1.13▼$6.47Volume43,743 shsAverage Volume1.04 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get LAVA Therapeutics alerts: Email Address LAVA Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside162.0% Upside$6.00 Price TargetShort InterestHealthy0.60% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.62Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.30) to ($1.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.04 out of 5 stars 3.5 Analyst's Opinion Consensus RatingLAVA Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLAVA Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about LAVA Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.60% of the float of LAVA Therapeutics has been sold short.Short Interest Ratio / Days to CoverLAVA Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in LAVA Therapeutics has recently decreased by 28.95%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLAVA Therapeutics does not currently pay a dividend.Dividend GrowthLAVA Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LVTX. Previous Next 2.0 News and Social Media Coverage News SentimentLAVA Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for LAVA Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for LVTX on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added LAVA Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, LAVA Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.79% of the stock of LAVA Therapeutics is held by insiders.Read more about LAVA Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for LAVA Therapeutics are expected to decrease in the coming year, from ($1.30) to ($1.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LAVA Therapeutics is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LAVA Therapeutics is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLAVA Therapeutics has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about LAVA Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsBig Tech is spending billions each month on Nvidia’s AI superprojectA small handful of Nvidia’s partners could see their own stocks surge upwards. They’re virtually unknown right now, but that won’t be the case much longer.Click here to find out who they are today. About LAVA Therapeutics Stock (NASDAQ:LVTX)LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.Read More LVTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LVTX Stock News HeadlinesJune 10 at 7:00 AM | globenewswire.comLAVA Announces Annual Meeting of ShareholdersJune 4, 2024 | americanbankingnews.comLAVA Therapeutics (NASDAQ:LVTX) Trading 8% Higher May 30, 2024 | globenewswire.comLAVA Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 21, 2024 | seekingalpha.comLAVA Therapeutics GAAP EPS of -$0.02 beats by $0.20, revenue of $6.99M beats by $3.49MMay 21, 2024 | globenewswire.comLAVA Provides Business Updates and Reports First Quarter 2024 Financial ResultsMay 6, 2024 | globenewswire.comLAVA Therapeutics to Participate in the Citizens JMP Life Sciences ConferenceMarch 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for LAVA Therapeutics Amid Promising T-Cell Cancer Therapy Trials and Strong FinancialsMarch 20, 2024 | finance.yahoo.comLAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial ResultsMarch 20, 2024 | globenewswire.comLAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial ResultsMarch 6, 2024 | finanznachrichten.deLAVA Therapeutics N.V.: LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)March 5, 2024 | msn.comLava gets $7M from Pfizer as trial for cancer drug advancesMarch 5, 2024 | globenewswire.comLAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)March 1, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: AdaptHealth (AHCO), LAVA Therapeutics (LVTX)February 21, 2024 | benzinga.comLAVA Therapeutics Stock (NASDAQ:LVTX), Short Interest ReportFebruary 14, 2024 | investing.comLAVA Therapeutics NV (LVTX)January 25, 2024 | msn.comLava signs collaboration agreement with MSD for prostate cancer therapyJanuary 25, 2024 | seekingalpha.comPCSA, ONCO and KAVL among mid-day moversJanuary 25, 2024 | finance.yahoo.comLAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®December 13, 2023 | ca.finance.yahoo.comLAVA Therapeutics N.V. (LVTX)November 11, 2023 | morningstar.comLAVA Therapeutics NV LVTXAugust 25, 2023 | bizjournals.comLava Therapeutics is latest life sciences company to trim its workforceAugust 22, 2023 | finanznachrichten.deLAVA Therapeutics N.V.: LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial ResultsAugust 22, 2023 | finance.yahoo.comLAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial ResultsJuly 6, 2023 | msn.comLAVA Therapeutics (LVTX) Price Target Decreased by 44.62% to 7.34June 14, 2023 | finanznachrichten.deLAVA Therapeutics N.V.: LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash RunwaySee More Headlines Receive LVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LAVA Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/21/2024Today6/12/2024Next Earnings (Estimated)8/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LVTX CUSIPN/A CIK1840748 Webwww.lavatherapeutics.com Phone31-85-016-3100FaxN/AEmployees37Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+162.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,970,000.00 Net Margins-228.02% Pretax Margin-225.81% Return on Equity-51.90% Return on Assets-26.33% Debt Debt-to-Equity Ratio0.01 Current Ratio7.42 Quick Ratio7.42 Sales & Book Value Annual Sales$6.77 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.39 per share Price / Book0.68Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable Beta0.59 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Stephen Allen Hurly M.B.A. (Age 56)M.Sc., CEO, President & Executive Director Mr. Fred M. Powell CPA (Age 63)Chief Financial Officer Dr. Hans van der Vliet M.D. (Age 50)Ph.D., Chief Scientific Officer Ms. Amy Garabedian J.D. (Age 48)General Counsel & Corporate Secretary Mr. Wouter van HunnikVP & Head of Human ResourcesDr. Ton Adang Ph.D. (Age 63)Chief Development Officer Dr. Charles Q. Morris M.D. (Age 59)MBChB, MRCP (UK), Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPOncoSec MedicalNASDAQ:ONCSQPharvarisNASDAQ:PHVSProcaps GroupNASDAQ:PROCView All CompetitorsInstitutional OwnershipPathway Financial Advisors LLCBought 14,000 shares on 4/10/2024Ownership: 0.000%View All Institutional Transactions LVTX Stock Analysis - Frequently Asked Questions Should I buy or sell LAVA Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LAVA Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LVTX shares. View LVTX analyst ratings or view top-rated stocks. What is LAVA Therapeutics' stock price target for 2024? 2 Wall Street analysts have issued 1 year price targets for LAVA Therapeutics' shares. Their LVTX share price targets range from $6.00 to $6.00. On average, they expect the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 162.0% from the stock's current price. View analysts price targets for LVTX or view top-rated stocks among Wall Street analysts. How have LVTX shares performed in 2024? LAVA Therapeutics' stock was trading at $1.58 on January 1st, 2024. Since then, LVTX stock has increased by 44.9% and is now trading at $2.29. View the best growth stocks for 2024 here. Are investors shorting LAVA Therapeutics? LAVA Therapeutics saw a drop in short interest in May. As of May 31st, there was short interest totaling 84,200 shares, a drop of 28.9% from the May 15th total of 118,500 shares. Based on an average daily trading volume, of 188,300 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.6% of the shares of the stock are sold short. View LAVA Therapeutics' Short Interest. When is LAVA Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 27th 2024. View our LVTX earnings forecast. How were LAVA Therapeutics' earnings last quarter? LAVA Therapeutics (NASDAQ:LVTX) released its quarterly earnings results on Tuesday, May, 21st. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.23. The firm earned $6.99 million during the quarter. LAVA Therapeutics had a negative trailing twelve-month return on equity of 51.90% and a negative net margin of 228.02%. When did LAVA Therapeutics IPO? LAVA Therapeutics (LVTX) raised $100 million in an initial public offering (IPO) on Thursday, March 25th 2021. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and SVB Leerink served as the underwriters for the IPO and Kempen & Co. was co-manager. Who are LAVA Therapeutics' major shareholders? LAVA Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Pathway Financial Advisors LLC (0.00%). How do I buy shares of LAVA Therapeutics? Shares of LVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LVTX) was last updated on 6/12/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredPotentially Pocket $767/Day with AIWhat if I told you it could take just $9… To win 90% of your options trades?Trade Machine | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredA once-in-a-century investment opportunityIt's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more poten...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share LAVA Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.